Mitogauzone, cisplatin, and vinblastine in advanced non-small cell lung cancer: A Southwest Oncology Group study

Robert Chapman, John Crowley, Joel G. Lucas, Ben Lin Hom, Robert B Livingston, Clarence B. Vaughn, Harry E. Hynes

Research output: Contribution to journalArticle

Abstract

This trial employing MGBG, vinblastine, and cisplatin in patients with advanced NSCLC produced a 10% response rate with no durable responses. This is disappointing compared to previously cited studies, although the median overall survival of 7.0 months is comparable. The relatively mild toxicity noted in this trial suggests that more aggressive use of the same combination may be feasible.

Original languageEnglish (US)
Pages (from-to)91-92
Number of pages2
JournalInvestigational New Drugs
Volume11
Issue number1
DOIs
StatePublished - Feb 1993
Externally publishedYes

Fingerprint

Mitoguazone
Vinblastine
Non-Small Cell Lung Carcinoma
Cisplatin
Survival

Keywords

  • cisplatin
  • mitogauzone
  • vinblastine

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Mitogauzone, cisplatin, and vinblastine in advanced non-small cell lung cancer : A Southwest Oncology Group study. / Chapman, Robert; Crowley, John; Lucas, Joel G.; Hom, Ben Lin; Livingston, Robert B; Vaughn, Clarence B.; Hynes, Harry E.

In: Investigational New Drugs, Vol. 11, No. 1, 02.1993, p. 91-92.

Research output: Contribution to journalArticle

Chapman, Robert ; Crowley, John ; Lucas, Joel G. ; Hom, Ben Lin ; Livingston, Robert B ; Vaughn, Clarence B. ; Hynes, Harry E. / Mitogauzone, cisplatin, and vinblastine in advanced non-small cell lung cancer : A Southwest Oncology Group study. In: Investigational New Drugs. 1993 ; Vol. 11, No. 1. pp. 91-92.
@article{546af25ad5a1481689f9ec9b50db727f,
title = "Mitogauzone, cisplatin, and vinblastine in advanced non-small cell lung cancer: A Southwest Oncology Group study",
abstract = "This trial employing MGBG, vinblastine, and cisplatin in patients with advanced NSCLC produced a 10{\%} response rate with no durable responses. This is disappointing compared to previously cited studies, although the median overall survival of 7.0 months is comparable. The relatively mild toxicity noted in this trial suggests that more aggressive use of the same combination may be feasible.",
keywords = "cisplatin, mitogauzone, vinblastine",
author = "Robert Chapman and John Crowley and Lucas, {Joel G.} and Hom, {Ben Lin} and Livingston, {Robert B} and Vaughn, {Clarence B.} and Hynes, {Harry E.}",
year = "1993",
month = "2",
doi = "10.1007/BF00873920",
language = "English (US)",
volume = "11",
pages = "91--92",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Mitogauzone, cisplatin, and vinblastine in advanced non-small cell lung cancer

T2 - A Southwest Oncology Group study

AU - Chapman, Robert

AU - Crowley, John

AU - Lucas, Joel G.

AU - Hom, Ben Lin

AU - Livingston, Robert B

AU - Vaughn, Clarence B.

AU - Hynes, Harry E.

PY - 1993/2

Y1 - 1993/2

N2 - This trial employing MGBG, vinblastine, and cisplatin in patients with advanced NSCLC produced a 10% response rate with no durable responses. This is disappointing compared to previously cited studies, although the median overall survival of 7.0 months is comparable. The relatively mild toxicity noted in this trial suggests that more aggressive use of the same combination may be feasible.

AB - This trial employing MGBG, vinblastine, and cisplatin in patients with advanced NSCLC produced a 10% response rate with no durable responses. This is disappointing compared to previously cited studies, although the median overall survival of 7.0 months is comparable. The relatively mild toxicity noted in this trial suggests that more aggressive use of the same combination may be feasible.

KW - cisplatin

KW - mitogauzone

KW - vinblastine

UR - http://www.scopus.com/inward/record.url?scp=0027191381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027191381&partnerID=8YFLogxK

U2 - 10.1007/BF00873920

DO - 10.1007/BF00873920

M3 - Article

C2 - 8394299

AN - SCOPUS:0027191381

VL - 11

SP - 91

EP - 92

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -